photodynamic therapy

Enhancement of Perylenequinonoid Compounds Production from Strain of Pseudoshiraia conidialis by UV-Induced Mutagenesis

mycolabadmin

Researchers used UV light to mutate fungal strains that naturally produce powerful medicinal compounds called perylenequinones. These compounds show promise for treating cancer and viral infections through photodynamic therapy. Through careful mutagenesis and screening, they developed a superior fungal strain that produces over 2100 mg/L of these valuable compounds, far exceeding previous methods. The breakthrough highlights that focusing on multiple beneficial compounds rather than just one can lead to better commercial applications.

Fruiting body-associated Pseudomonas contact triggers ROS-mediated perylenequinone biosynthesis in Shiraia mycelium culture

mycolabadmin

Scientists discovered that bacteria living inside medicinal mushroom fruiting bodies can trigger the production of powerful healing compounds called perylenequinones through direct physical contact. These compounds are being used to fight cancer and harmful bacteria through a therapy called photodynamic therapy. The study shows that when bacteria touch the mushroom’s cells, it causes the mushroom to produce more of these therapeutic compounds by creating controlled stress that activates specific genes.

Synthesis, Physicochemical Properties and Anti-Fungal Activities of New Meso-Arylporphyrins

mycolabadmin

Researchers created three new porphyrin compounds that effectively kill fungal infections like Candida and athlete’s foot fungi. These compounds can also generate singlet oxygen when exposed to light, making them potentially useful for photodynamic therapy treatments. Testing showed they inhibited fungal growth at relatively low concentrations, suggesting they could become new antifungal medications.

Production of fungal hypocrellin photosensitizers: Exploiting bambusicolous fungi and elicitation strategies in mycelium cultures

mycolabadmin

Hypocrellins are powerful compounds from fungi that can treat cancers and infections through light-activated therapy. Since wild sources are limited, scientists are growing these fungi in laboratory cultures and using special techniques to boost production. This review summarizes the best methods for producing hypocrellins, from choosing the right fungal strains to optimizing growing conditions and using natural stimulants to increase yields.

Glucose-6-Phosphate Dehydrogenase Modulates Shiraia Hypocrellin A Biosynthesis Through ROS/NO Signaling in Response to Bamboo Polysaccharide Elicitation

mycolabadmin

Researchers discovered that a naturally derived compound from bamboo boosts the production of hypocrellin A, a promising cancer-fighting and antimicrobial agent made by a special fungus. By studying a key enzyme called G6PDH, they found that it acts as a molecular switch controlling hypocrellin production when the fungus senses bamboo components. This discovery enables cost-effective large-scale production of this powerful medicine through simple fermentation, potentially making novel cancer treatments and antibiotics more accessible.

Natural Antimicrobial Compounds as Promising Preservatives: A Look at an Old Problem from New Perspectives

mycolabadmin

This review examines natural alternatives to synthetic food preservatives, which are increasingly recognized as potentially harmful. Natural antimicrobial compounds from plants, fungi, and other sources can effectively prevent food spoilage and bacterial contamination. New technologies using light and ultrasound can enhance these natural compounds’ effectiveness. While promising, these natural preservatives need more research and regulatory approval before widespread industrial use.

Caged-hypocrellin mediated photodynamic therapy induces chromatin remodeling and disrupts mitochondrial energy metabolism in multidrug-resistant Candida auris

mycolabadmin

Researchers developed a new photodynamic therapy treatment using a light-activated compound called COP1T-HA to fight drug-resistant Candida auris infections. The therapy works by reorganizing the fungal cell’s genetic material architecture and disrupting energy production in mitochondria, ultimately killing the fungal cells. This approach represents a novel strategy to overcome antibiotic resistance, as it targets multiple cellular processes rather than a single pathway that fungi can easily resist.

Energy Metabolism Enhance Perylenequinone Biosynthesis in Shiraia sp. Slf14 through Promoting Mitochondrial ROS Accumulation

mycolabadmin

Scientists studied two similar fungi to understand how one produces more of a beneficial compound called perylenequinones (PQs), which have medical uses against infections and cancer. They discovered that the high-producing strain uses energy more efficiently, which causes tiny structures in the cells called mitochondria to produce reactive molecules (ROS). These reactive molecules trigger the fungus to make more PQs as a protective response. By controlling these processes, researchers can potentially improve the production of this valuable medicine.

Improving treatment of chromoblastomycosis: the potential of COP1T-HA and antimicrobial photodynamic therapy against Fonsecaea monophora in vitro

mycolabadmin

Chromoblastomycosis is a stubborn skin fungal infection that is difficult to treat with current medications and often comes back after treatment. Researchers tested a new treatment using a special light-activated compound called COP1T-HA combined with blue light, which successfully killed the fungus in laboratory tests. The treatment worked quickly and at low doses, showing promise as a potential new therapy for this challenging infection.

Glucose-6-Phosphate Dehydrogenase Modulates Shiraia Hypocrellin A Biosynthesis Through ROS/NO Signaling in Response to Bamboo Polysaccharide Elicitation

mycolabadmin

Researchers discovered that a specific enzyme called glucose-6-phosphate dehydrogenase (G6PDH) controls the production of hypocrellin A, a powerful therapeutic compound found in Shiraia fungi. When bamboo polysaccharides are added to fungal cultures, they trigger G6PDH activity, which then increases the production of signaling molecules that boost hypocrellin A biosynthesis. This finding could lead to better ways to produce this promising cancer-fighting photosensitizer at industrial scales using simple, cost-effective methods.

Research Keyword: photodynamic therapy